Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Zendy

Mansoor Husain | Zendy; Andreas L. Birkenfeld | Zendy; Morten Donsmark | Zendy; Kathleen Dungan | Zendy; Freddy G. Eliaschewitz | Zendy; Denise Reis Franco | Zendy; Ole K. Jeppesen | Zendy; Ildiko Lingvay | Zendy; Ofri Mosenzon | Zendy; Sue D. Pedersen | Zendy; Cees J. Tack | Zendy; Mette S. Thomsen | Zendy; Tina Vilsbøll | Zendy; Mark Warren | Zendy; Stephen C. Bain | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Author(s) -

Mansoor Husain,

Andreas L. Birkenfeld,

Morten Donsmark,

Kathleen Dungan,

Freddy G. Eliaschewitz,

Denise Reis Franco,

Ole K. Jeppesen,

Ildiko Lingvay,

Ofri Mosenzon,

Sue D. Pedersen,

Cees J. Tack,

Mette S. Thomsen,

Tina Vilsbøll,

Mark Warren,

Stephen C. Bain

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1901118

Subject(s) - semaglutide , medicine , type 2 diabetes , agonist , diabetes mellitus , glucagon like peptide 1 receptor , dulaglutide , exenatide , endocrinology , receptor , liraglutide

In this trial involving patients with type 2 diabetes, the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo. (Funded by Novo Nordisk; PIONEER 6 ClinicalTrials.gov number, NCT02692716.).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research